SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)
$GNMK
Medical/Dental Instruments
Health Care
Save time and jump to the most important pieces.
BTIG downgraded GenMark Diagnostics from Buy to Neutral
Cowen & Co. downgraded GenMark Diagnostics from Outperform to Market Perform and set a new price target of $24.05 from $23.00 previously
Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold
Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123 Browse in-de
Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of March 12, 2021 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Geronimo Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and GenMark. The tender offer period will expire at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, April 21, 2021, unless the offer is extended. Roche
Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sampleGenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections Basel, 15 March 2021 - Roc
15-12B - GenMark Diagnostics, Inc. (0001487371) (Filer)
EFFECT - GenMark Diagnostics, Inc. (0001487371) (Filer)
S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)
4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)
4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)
4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)
SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)
SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)
SC 13D - GenMark Diagnostics, Inc. (0001487371) (Subject)